Fiserv Inc. Common Stock vs Inovio Pharmaceuticals Inc — how do they compare? Fiserv Inc. Common Stock trades at $46.17 (market cap $24.81B), while Inovio Pharmaceuticals Inc trades at $0.96 (market cap $103.19M). The key difference: Fiserv Inc. Common Stock is far larger — about 240.4× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Fiserv Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiserv Inc. Common Stock for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FISV | INO | |
|---|---|---|
Market Cap | $24.81B | $103.19M |
Volume | 4,091,234 | 8,461,580 |
Sector | Technology | Health |
52-Week High | $126.54 | $2.60 |
52-Week Low | $44.36 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $52.60B | $74.52M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Fiserv, Inc. is a global provider of payments and financial services technology, offering merchant acquiring, digital commerce, and financial solutions through its Merchant Solutions and Financial Solutions segments.
Read more on FISV →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →